Corvus Pharmaceuticals closed at $10.57 on Nov 4, up 7.53%, 58.6% below its 52-week closing high. Volume of 2.0M shares was 1.92× its 20-day average (above normal).
Split-adjusted performance: +0.1% over one month, -31.6% over six months, +37.6% over one year.
Short interest was 18.0M shares at the Oct 15 settlement (25.5% of float, 14.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals | $10.57 | +7.53% | −31.6% | — | — | — | $889.2M | |
| ANROAlto Neuroscience | $23.30 | +2.64% | −4.9% | — | — | — | $914.3M | Compare |
| ARDXArdelyx | $3.29 | +8.58% | −53.7% | +15.7% | −0.6% | — | $849.4M | Compare |
| LTGOLatigo Biotherapeutics | $14.04 | −3.64% | — | — | — | — | $930.8M | Compare |
| ALMSAlumis | $6.55 | +0.77% | −74.3% | −37.7% | −8557.2% | — | $847.8M | Compare |
| SNDXSyndax Pharmaceuticals | $10.45 | −26.87% | −49.4% | +81.6% | −59.3% | — | $933.2M | Compare |
| CYRXCryoPort | $16.70 | +1.52% | +31.6% | +7.7% | −20.9% | — | $845.8M | Compare |
| AKTSAktis Oncology | $15.20 | +1.74% | −24.1% | — | −713.5% | — | $845.4M | Compare |
| JBIOJade Biosciences | $15.04 | +3.23% | −40.2% | — | — | — | $956.5M | Compare |
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
